文献速递自身免疫性与大疱性皮肤病

免疫检查点抑制剂相关自身免疫性大疱病:临床综述

Immune checkpoint inhibitor-associated autoimmune bullous disease: A clinical review.
PubMed 文献 · J Am Acad Dermatol · 2026-06-12

本临床综述探讨免疫检查点抑制剂(ICI)触发的免疫性大疱性皮肤病的发病机制、临床表现、诊断与管理策略,强调其常模仿经典自身免疫性大疱病但具有迟发、黏膜倾向和停药后持续等独特考虑,诊断依赖临床怀疑、组织病理、直接和间接免疫荧光及酶联免疫吸附试验,管理通常使用糖皮质激素和免疫抑制剂,生物制剂用于难治性病例,ICI是否继续需个体化评估以平衡肿瘤控制与自身免疫毒性。

要点

  • ICI相关免疫性大疱病可表现为大疱性类天疱疮、寻常型天疱疮等多种类型。
  • 诊断依赖临床怀疑、组织病理、直接和间接免疫荧光及酶联免疫吸附试验。
  • 管理常用糖皮质激素和免疫抑制剂,难治病例可选用利妥昔单抗、度普利尤单抗和奥马珠单抗。

核心结论

  • ICI相关免疫性大疱病模仿经典自身免疫性大疱病,但具有迟发、黏膜倾向和停药后持续等独特临床考虑。
  • ICI继续与否需个体化评估,平衡肿瘤控制与自身免疫毒性。

研究设计与样本

  • 临床综述,探讨ICI触发的免疫性大疱性皮肤病的发病机制、临床表现、诊断和管理策略。

主要发现

  • ICI相关免疫性大疱病包括大疱性类天疱疮、寻常型天疱疮、线状IgA大疱性皮病、黏膜类天疱疮、副肿瘤性天疱疮、疱疹样皮炎和扁平苔藓类天疱疮。
  • 这些疾病常具有迟发、黏膜倾向和停药后持续等独特临床考虑。

关键数值与推荐

  • 诊断评估依赖临床怀疑、组织病理学、直接和间接免疫荧光及酶联免疫吸附试验。
  • 管理通常包括糖皮质激素和免疫抑制剂,生物制剂如利妥昔单抗、度普利尤单抗和奥马珠单抗用于难治性病例。

临床怎么用

  • 皮肤科和肿瘤科团队需共同平衡减轻自身免疫毒性与保留肿瘤获益的双重优先事项。
  • ICI是否继续需个体化评估,综合考虑肿瘤控制和自身免疫毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immune checkpoint inhibitors (ICIs) have markedly advanced oncology by enhancing the immune system's ability to combat malignancies. However, their use is increasingly associated with immune-related adverse events, including immunobullous dermatoses. These disorders, such as bullous pemphigoid, pemphigus vulgaris, linear immunoglobulin A bullous dermatosis, mucous membrane pemphigoid, paraneoplastic pemphigus, dermatitis herpetiformis, and lichen planus pemphigoides present significant diagnostic and therapeutic challenges. This clinical review explores the pathogenesis, clinical presentation, diagnosis, and management strategies of immunobullous dermatoses triggered by ICIs, highlighting the complex relationship between effective cancer treatment and immune regulation. ICI-induced immunobullous dermatoses closely mimic their conventional autoimmune counterparts but often have unique clinical considerations, such as delayed onset, mucosal predilection, and persistence post-discontinuation of medication. Diagnostic evaluation relies on clinical suspicion, histopathology, direct and indirect immunofluorescence, and enzyme-linked immunosorbent assays. Management typically involves corticosteroids and immunosuppressants, with biologics such as rituximab, dupilumab and omalizumab reserved for refractory cases. Decisions regarding the continuation of ICIs require individualized assessment, balancing cancer control with autoimmune toxicity. Dermatologic and oncologic teams must navigate dual priorities of mitigating autoimmune toxicity and preserving oncologic benefit.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Nukaly HY, Barnawi G, Thalib HI, et al. Immune checkpoint inhibitor-associated autoimmune bullous disease: A clinical review. J Am Acad Dermatol. 2026. PMID: 42285257. doi:10.1016/j.jaad.2026.06.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。